Literature DB >> 26505921

Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.

Justin R Tse1, Bita V Naini1, David S K Lu1, Steven S Raman1.   

Abstract

PURPOSE: To determine which clinical variables and gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) imaging features are associated with histologically proved hepatocellular adenoma (HCA) genotypic subtypes.
MATERIALS AND METHODS: In this institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study, clinical information and MR images of 49 histologically proved HCAs from January 2002 to December 2013 (21 patients; mean age, 39 years; age range, 15-59 years) were retrospectively reviewed by two radiologists. Qualitative and quantitative imaging features, including the signal intensity ratio relative to liver in each phase, were studied. HCA tissues were stained with subtype-specific markers and subclassified by a pathologist. Clinical and imaging data were correlated with pathologic findings and compared by using Fisher exact or t test, with a Bonferroni correction for multiple comparisons.
RESULTS: Forty-nine HCAs were subclassified into 14 inflammatory, 20 hepatocyte nuclear factor (HNF)-1α-mutated, one β-catenin-activated, and 14 unclassified lesions. Intralesional steatosis was exclusively seen in HNF-1α-mutated lesions. Marked hyperintensity on T2-weighted images was seen in 12 of 14 (86%) inflammatory lesions compared with four of 21 (19%) HNF-1α-mutated, seven of 14 (50%) unclassified, and zero of one (0%) β-catenin-activated lesion. Two large lesions (one β-catenin-activated and one unclassified) transformed into hepatocellular carcinomas and were the only lesions to enhance with marked heterogeneity. In the hepatobiliary phase, all HCA subtypes were hypoenhancing compared with surrounding liver parenchyma, and they reached their nadir signal intensity by 10 minutes after the administration of contrast material before plateauing. HNF-1α-mutated lesions had the lowest lesion signal intensity ratio of 0.47 ± 0.09, compared with 0.73 ± 0.18 for inflammatory lesions (P = .0004), 0.82 for the β-catenin-activated lesion, and 0.73 ± 0.06 for the unclassified lesion (P = .00002).
CONCLUSION: In this study, all HCA subtypes were hypoenhancing at Gd-EOB-DTPA-enhanced MR imaging in the hepatobiliary phase and reached their nadir signal intensity at 10 minutes. HNF-1α-mutated lesions could be distinguished from other subtypes by having the lowest lesion signal intensity ratio.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26505921     DOI: 10.1148/radiol.2015142449

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  13 in total

1.  Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.

Authors:  Edouard Reizine; Maxime Ronot; Frederic Pigneur; Yvonne Purcell; Sebastien Mulé; Marco Dioguardi Burgio; Julien Calderaro; Giuliana Amaddeo; Alexis Laurent; Valérie Vilgrain; Alain Luciani
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

2.  Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival.

Authors:  Ji Hye Min; Tae Wook Kang; Young Kon Kim; Seong Hyun Kim; Kyung Sook Shin; Jeong Eun Lee; Sang Yun Ha; Insuk Sohn
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

Review 3.  Liver Masses: What Physicians Need to Know About Ordering and Interpreting Liver Imaging.

Authors:  Arman Sheybani; Ron C Gaba; R Peter Lokken; Senta M Berggruen; Winnie A Mar
Journal:  Curr Gastroenterol Rep       Date:  2017-10-18

4.  Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.

Authors:  Edouard Reizine; Giuliana Amaddeo; Frederic Pigneur; Laurence Baranes; François Legou; Sebastien Mulé; Benhalima Zegai; Vincent Roche; Alexis Laurent; Alain Rahmouni; Julien Calderaro; Alain Luciani
Journal:  Eur Radiol       Date:  2018-05-02       Impact factor: 5.315

5.  Unclassified hepatocellular adenoma in a middle-aged woman with glucose intolerance.

Authors:  Kumi Ozaki; Kenichi Harada; Toru Yamamoto; Hiroyuki Aoyagi; Yasuharu Kaizaki; Jun Yoshikawa
Journal:  Clin J Gastroenterol       Date:  2017-11-07

6.  Transient severe motion during arterial phase in patients with Gadoxetic acid administration: Can a five hepatic arterial subphases technique mitigate the artifact?

Authors:  Yu-Dong Xiao; Cong Ma; Jun Liu; Hua-Bing Li; Shun-Ke Zhou; Zi-Shu Zhang
Journal:  Exp Ther Med       Date:  2018-01-17       Impact factor: 2.447

Review 7.  Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review.

Authors:  Yongfei Guo; Wenjuan Li; Wenli Cai; Yi Zhang; Yijie Fang; Guobin Hong
Journal:  Int J Med Sci       Date:  2017-06-23       Impact factor: 3.738

8.  Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis.

Authors:  Yongfei Guo; Wenjuan Li; Zhinan Xie; Yi Zhang; Yijie Fang; Wenli Cai; Guobin Hong
Journal:  J Cancer       Date:  2017-05-11       Impact factor: 4.207

Review 9.  Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.

Authors:  Jae Hyun Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

Review 10.  MRI of paediatric liver tumours: How we review and report.

Authors:  Susan C Shelmerdine; Derek J Roebuck; Alexander J Towbin; Kieran McHugh
Journal:  Cancer Imaging       Date:  2016-08-15       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.